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Objective: TNF-α and IL-17A act on fibroblast-like synoviocytes (FLS) and contribute to
cytokine production, inflammation, and tissue destruction in rheumatoid arthritis (RA). The
aim of this study was to compare their effects on osteogenic differentiation of isolated FLS
and on whole bone explants from RA and osteoarthritis (OA) patients.
Methods: Fibroblast-like synoviocytes and bone explants were cultured in the presence or
absence ofTNF-α and/or IL-17A. Mineralization of extracellular matrix of FLS was measured
by alizarin red and alkaline phosphatase activity (ALP). mRNA expression was analyzed
by qRT-PCR for Wnt5a, BMP2, and RUNX2, key genes associated with osteogenesis. IL-6
and IL-8 levels were measured by enzyme-linked immunosorbent assays. Bone explant
structure was quantified by histomorphometry.
Results: In isolated OA and RA FLS, the combination of TNF-α and IL-17A induced matrix
mineralization, increased ALP activity and expression of the osteogenesis-associated
genes Wnt5a, BMP2, and Runx2, indicating an osteogenic differentiation. Wnt5a levels
increased with TNF-α alone and in combination with IL-17A. BMP2 expression decreased
with IL-17A and TNF-α after 12 h with OA FLS and 24 h with RA FLS. Runx2 expression
decreased only with combination of TNF-α and IL-17A in OA FLS and with cytokines alone
and combined in RA FLS. IL-6 and IL-8 production increased with IL-17A and/or TNF-α in
both FLS and bone samples, especially from RA.Treatment of bone explants with cytokine
combination increased ALP in OA but not RA samples. A decrease in bone volume was
seen with cytokine combination, especially with RA explants.
Conclusion: Differences were observed for the effects of IL-17A and TNF-α on osteogenic
differentiation. In isolated FLS, increased osteoblastogenesis was observed, contrasting
with the inhibitory effect in whole bone, specifically in RA. The net effect of IL-17A and
TNF-α appears to depend on the disease state and the presence of other cells.
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INTRODUCTION
Arthritis diseases are associated with various local bone changes.
Rheumatoid arthritis (RA) is characterized by destruction of
bone, and defective repair leading to rapid joint destruc-
tion. Osteoarthritis (OA) is characterized by simultaneous bone
destruction and osteophyte formation, leading to a lower speed
of joint destruction. Fibroblast-like synoviocytes (FLS) are the
predominating cells in the synovium, and play a central role in
defining the stromal environment within arthritic bone diseases.
Abbreviations: ALP, alkaline phosphatase; BMP-2, bone morphogenetic protein-
2; FLS, fibroblast-like synoviocytes; OA, osteoarthritis; RA, rheumatoid arthri-
tis; Runx2, runt-related transcription factor-2; Wnt5a, wingless-type MMTV
integration site family, member 5A.
In vitro studies have shown that FLS cultured in osteogenic
medium undergo osteogenic differentiation with a significant
increase in alkaline phosphatase and calcium deposits (1, 2). How-
ever, the effects of inflammation and of cytokines in the context
are unknown.
Bone homeostasis is maintained by the balance of bone resorp-
tion, mediated by osteoclasts (OCs) (3) and bone formation,
mediated by osteoblasts (OBs) (4). Most of the in vitro stud-
ies on bone homeostasis usually covered only one aspect of this
balance, either bone formation or destruction, using isolated cell
types. However, a complex system exists in vivo with interactions
between bone cells (OCs, OBs, osteocytes), bone marrow cells, and
a complex network of cytokines, hormones, and other signaling
molecules under the influence of mechanical stimuli (5–9).
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In the context of arthritic diseases, this occurs through local
production of pro-inflammatory cytokines, like TNF-α and IL-
17A, small molecule mediators of inflammation, and proteolytic
enzymes that degrade the extracellular matrix leading to bone and
cartilage destruction (10–14). Most of the ex vivo models have sug-
gested inhibition of TNF-α and IL-17A to control bone destruction
(15–19). However, recent studies have shown that TNF-α and
IL-17A may induce bone formation in vitro (20–23).
We have previously studied the effects of IL-17A and TNF-α
on the in vitro osteogenic differentiation of bone marrow-derived
mesenchymal cells from normal individuals (23). In the context of
local arthritis, it has been well established that chronic inflamma-
tion induces overtime various epigenetic changes in mesenchymal
cells. When comparing RA to OA FLS, one major effect of IL-17
was the acquisition of a defective apoptosis in RA FLS, contribut-
ing chronicity (24, 25). To study joint-derived mesenchymal cells,
which have been exposed to this long-lasting inflammatory stress,
we used isolated OA and RA FLS as they are easy to obtain
and compared their response to IL-17A and TNF-α regarding
osteogenic differentiation and cytokine production. We then com-
pared the effects of these cytokines on isolated cells and on ex
vivo bone explants from OA and RA patients. Matrix mineraliza-
tion, alkaline phosphatase (ALP), cytokines, and key regulatory
genes of osteogenesis were examined for the in vitro FLS model.
ALP, cytokines, and histomorphometry were used for ex vivo
studies.
MATERIALS AND METHODS
PATIENTS
Bone explants were obtained from the tibia and femoral head
from 13 patients undergoing orthopedic surgery for joint replace-
ment (3 RA and 10 OA; 4 males/9 females; age 62.0± 14.3 years).
RA and OA patients fulfilled the American College of Rheuma-
tology criteria for RA and OA (26, 27). Each individual signed an
informed consent and the protocol was approved by the committee
for protection of persons participating in biomedical research.
PREPARATION AND CULTURE OF BONE EXPLANTS AND SYNOVIAL
CELLS
Bone samples were obtained under sterile conditions and imme-
diately placed in phosphate buffer saline (PBS) containing antibi-
otics. Sample were cut into pieces of ~500 mm3, and cultured
in complete αMEM medium (Lonza, Verviers, Belgium) sup-
plemented with 10% FBS (Hyclone, Thermo scientific, South
America), 2 mM l-glutamine, 100 U/ml penicillin, streptomycin
at 37°C in a humidified environment of 5% CO2, and 95%
air. Cultures were performed in six well-plates (Falcon) with
one piece of bone in a final volume of 8 ml, and in the pres-
ence or absence of 1 ng/ml TNF-α and/or 50 ng/ml IL-17A
(R&D systems, Lille, France). Supernatants were harvested after
7 days of culture, and the remaining bone samples were used for
histomorphometry.
Fibroblast-like synoviocytes were obtained from the synovial
tissue of hips or knees from three RA and three OA patients. FLS
were isolated by enzyme digestion and cultured at 37°C in DMEM
medium (Eurobio, Courtaboeuf, France) supplemented with 10%
fetal bovine serum (Thermo scientific, Saint Aubin, France), 2 mM
l-glutamine, 100 U/ml penicillin, streptomycin. FLS were then
used for osteogenic differentiation (23).
MINERALIZATION ASSAY
Cells were washed twice with PBS, fixed with 70% cooled ethanol
for 1 h, and washed with water. Cells were stained for 20 min at
ambient temperature with alizarin red (pH: 4.2, 40 min, Sigma,
Saint Quentin-Fallavier, France) and examined under light micro-
scope. The red color referred to calcium deposit was quantified.
The alizarin scale is defined as the average of clusters counted
under microscope divided by 10 to simplify the scale.
ALKALINE PHOSPHATASE ASSAY
Wells were washed twice to remove any dead cell, then super-
natants of cell lysates were collected, and protein content was
determined using the Bradford protein assay (Sigma). Ten micro-
liters from the supernatants were mixed with 20µl of MUP, used
as a substrate (Abcam, Paris, France) in a 96-well plate, and
incubated at room temperature for 30 min. Fluorescence inten-
sity was measured at excitation/emission 360/440 nm. The ALP
activity was normalized to protein content and expressed as U/µg
protein.
QUANTITATIVE RT-PCR ANALYSIS
RNA was purified using RNeasy kits (Qiagen, Les Ulis, France).
The concentration of RNA was quantified by spectrophotome-
try (SmartSpec™ 3000, Biorad, Hercules, CA, USA). Total RNA
(500 ng) was reverse transcribed with the QuantiTec Reverse
Transcription (Qiagen Kit) into cDNA. PCR amplification was
performed on a LightCycler (Roche Diagnostics, Switzerland)
using Fast-Start™ DNA Master SYBR Green I real-time PCR kit
(Roche Molecular Biochemicals, Switzerland). The expression of
the genes was normalized to the expression of human cyclophilin
B (CPB) (5′tgtggtgtttggcaaagttc3′; 3′gtttatcccggctgtctgtc5′) (Qia-
gen). The list of primers (Qiagen) is as follows: BMP2 (5′ccaccatga
agaatctttgga3′; 3′gagttggctgttgcaggttt5′), RUNX2 (5′gtggacgaggcaa
gagttt3′; 3′tggggtctgtaatctgactc5′),Wnt5a (5′attcttggtggtcgctaggt3′;
3′accttcgatgtcggaattgat5′).
ENZYME-LINKED IMMUNOSORBENT ASSAYS
Concentrations of IL-6 and IL-8 were evaluated with commercial
enzyme-linked immunosorbent assays (ELISA) kits, according to
the manufacturer’s instructions (R&D systems, Lille, France).
BONE HISTOMORPHOMETRY
This study was performed as previously described (28, 29). Bone
pieces were fixed in cold 4.5% formalin (pH 7.4) and embedded
in methylmethacrylate (Merck, Fribourg, Germany) at −20°C.
Sections of 8µm were prepared with a microtome (Polycut E,
Reichert-Jung, Germany) and stained with Solochrome cyanin
R, and Goldner’s (all reagents from Merck). Histomorphomet-
ric parameters were measured with automatic image analyzer at
low power field (×1) (Imager A1, Axio, Zeiss, Germany).
STATISTICAL ANALYSIS
Analysis was performed using a Wilcoxon test from Graphpad
Prism. p Values were determined taking into account the number
of samples from different patient and the number of replicates per
assay. p Values of <0.05 were considered significant.
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RESULTS
TNF-α AND IL-17A INCREASED MINERALIZATION OF THE
EXTRACELLULAR MATRIX IN ISOLATED SYNOVIOCYTES
Mineralization of the extracellular matrix is one of the key bone
formation markers and is influenced by cytokines (30). To eval-
uate the effects of TNF-α and/or IL-17A on matrix mineraliza-
tion, FLS from OA and RA patients were cultured for 17 days in
osteogenic medium with and without cytokines. Alizarin red stain-
ing was used to visualize mineralization. As shown in Figure 1A,
row 2, culture of FLS with osteogenic factors alone induced a
weak matrix mineralization, which appeared at day 17 in both
cell types. In OA-FLS, both TNF-α and IL-17A enhanced signif-
icantly this mineralization at day 17 (Figure 1A, row 3 and 4;
Figure 1B). In RA FLS, TNF-α but not IL-17A alone enhanced
matrix mineralization (Figure 1A, row 4; Figure 1B). Moreover,
the combination of TNF-α and IL-17A highly enhanced the min-
eralization in both cell types (Figure 1A, column 5). Thus, these
results show that TNF-α alone enhanced bone mineralization,
while a potentiation was observed upon combination of TNF-α
and IL-17A.
IL-17A AND TNF-α INCREASED ALP ACTIVITY IN VITRO BUT NOT
EX VIVO
Next we investigated the effects of TNF-α and IL-17A on ALP,
an enzyme essential for bone mineralization (31). ALP activity
was measured at day 7 and 14 (Figure 2). In OA and RA FLS,
TNF-α and IL-17A alone or combined increased ALP activity at
day 7 (Figures 2A,B). Day 14 shows no more difference between
osteogenic medium alone and cytokines in OA FLS (Figure 2A),
while in RA FLS, TNF-α alone or in combination to IL-17A
showed a significant increase (6-fold with TNF-α and 7.3-fold
with TNF-α+ IL-17A vs. 2.2-fold without cytokine, **p< 0.005).
The combination of both cytokines showed a more potent effect
on RA than OA FLS.
In parallel, ALP was measured in the supernatants of OA and
RA bone samples cultured for 7 days. TNF-α and IL-17A alone
induced a non-significant increase in OA but not in RA sam-
ples. A significant increase was seen with the combination of both
cytokines in OA but not RA samples (Figure 2C). RA bone sam-
ples appeared thus insensitive to the effect of cytokines. Therefore,
these results showed that in vitro, IL-17A and TNF-α combination
increased ALP in OA FLS, with increased sensitivity in RA FLS,
while ex vivo, only OA bone samples showed a limited response.
IL-17A AND TNF-α INCREASED OSTEOGENIC GENE EXPRESSION IN FLS
To better understand the effects of TNF-α and IL-17A on
osteogenic differentiation of FLS, mRNA expression levels of
osteogenic genes like BMP2 (32), Wnt5a (33), and Runx2 (34)
were measured at 6, 12, and 24 h.
Bone morphology protein 2 (BMP2) is known to induce OB
differentiation (32). At 6 h, TNF-α alone and combined with IL-
17A increased BMP2 expression levels in RA but not OA FLS.
IL-17A alone had no effect. Compared to 6 h levels, BMP2 expres-
sion decreased over time in the presence of IL-17A and TNF-α in
OA FLS (1 vs. 0.68 vs. 0.16-fold decrease at 6, 12, and 24 h, respec-
tively), while it started decreasing at 24 h in RA FLS (1.8-fold with
IL-17A+TNF-α at 6 and 12 h vs. 0.42-fold with TNF-α+ IL-17A
at 24 h) (Figure 3A). Moreover, this increase in BMP2 expression
FIGURE 1 | Effects of IL-17A and/orTNF-α on extracellular matrix
of synoviocytes. FLS were cultured at a density 5×103 cell/cm2.
(A) In the absence (column 1, negative control as basic DMEM
medium without any addition) or presence (column 2) of osteogenic
factors. TNF-α 1 ng/ml (column 3) or IL-17A 50 ng/ml (column 4), or
both (column 5) were added or not to cultures. After 7, 14, and
17 days, cells were stained with alizarin red and (B) calcium deposits
were quantified and analyzed for each condition using the Wilcoxon
test *p< 0.05, **p<0.005, ***p<0.0005 vs. induction medium
alone, #p<0.05, ##p<0.005 TNF-α alone vs. IL-17A and IL-17A+TNF-α,
###p<0.0005 IL-17A vs. IL-17A+TNF-α. The bars of each graph
represent mean+SEM.
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FIGURE 2 | Effects of IL-17A and/orTNF-α on alkaline
phosphatase activity. (A) OA and (B) RA FLS were cultured at a
density 5×103 cell/cm2 in osteogenic medium in the absence (0) or
presence of TNF-α 1 ng/ml and/or IL-17A 50 ng/ml for 14 days. (C) Bone
samples were cultured in six well-plates for 7 days. Supernatants
were collected for ALP measurements by fluorometry. Results were
analyzed using the Wilcoxon test. **p< 0.005 vs. osteogenic
medium alone, #p< 0.05, ##p<0.005 TNF-α alone vs. IL-17A and
IL-17A+TNF-α, ##p<0.005 IL-17A vs. IL-17A+TNF-α. The bars of each
graph represent mean+SEM.
was more potent in RA than OA-FLS (1.8-fold increase with
IL-17A+TNF-α compared to control without cytokines in RA
FLS at 12 h vs. 0.68-fold in OA FLS, **p< 0.005).
Wnt5a plays an important role in the development of bone
and induces osteoblastogenesis (33). Basal Wnt5a expression lev-
els did not change over time. IL-17A alone had no significant
effect on Wnt5a expression, while TNF-α alone or in combina-
tion with IL-17A induced a significant increase after 12 h in both
OA and RA FLS (1.6-fold increase with IL-17A+TNF-α vs. 0.9-
fold without cytokines in OA FLS, **p< 0.005; 1.4-fold increase
with IL-17A+TNF-α vs. 0.9-fold without cytokines in RA FLS,
*p< 0.05) (Figure 3B).
Runx2 is a key transcription factor for osteogenesis (34). Runx2
mRNA expression increased over time as early as 12 h in OA
and RA FLS (1-fold without cytokines at 6 h vs. 5-fold at 12 h
in OA FLS; 1-fold without cytokines at 6 h vs. 3.6-fold at 12 h
in RA FLS) (Figure 3C), which is consistent with the ongoing
osteogenic differentiation. Cytokine treatment decreased Runx2
expression in OA and RA FLS at early time points (0.6-fold with
IL-17A+TNF-α vs. 1-fold without cytokines in OA FLS and 0.5-
fold with IL-17A+TNF-α vs. 1-fold without cytokines in RA FLS
at 6 h, **p< 0.005), whereas, at later time points, these cytokines
had no effect on Runx2 expression.
Therefore, these results show that IL-17A and TNF-α combi-
nation induced significant changes in osteogenic gene markers of
both FLS, specifically with RA FLS.
POTENTIATION EFFECTS OF IL-17A AND TNF-α ON IL-6 AND IL-8
PRODUCTION IN VITRO AND EX VIVO
TNF-α and IL-17A are known to induce IL-6 and IL-8 produc-
tion, with IL-6 being a key cytokine for osteoclastogenesis (35,
36). Treatment with IL-17A and TNF-α alone or combined for
7 and 14 days induced IL-6 and IL-8 production in both in vitro
and ex vivo models, especially with IL-17A and TNF-α combina-
tion (Figure 4). In vitro, levels were higher in RA compared to
OA FLS at both 7 and 14 days, for both IL-6 (9.4-fold with TNF-
α+ IL-17A vs. 0.6-fold without cytokines for OA FLS, **p< 0.005;
17-fold with TNF-α+ IL-17A vs. 2.5-fold without cytokines for
RA FLS, **p< 0.005), and IL-8 (3-fold with TNF-α+ IL-17A vs.
0.4-fold without cytokines OA, **p< 0.005; 13.8-fold with TNF-
α+ IL-17A vs. 2.2-fold without cytokines RA, ***p< 0.0005)
(Figures 4A,B).
Ex vivo results with bone samples showed changes in accor-
dance with those obtained in vitro, where IL-17A and/or TNF-α
increased significantly IL-6 and IL-8 production (Figures 4C,D).
However, bone samples from RA patients showed reduced reac-
tivity compared to bone samples from OA patients, possibly as
a consequence of previous in vivo exposure to the same factors.
Thus, these results showed that IL-17A and TNF-α exerted the
same effect on IL-6 and IL-8 production in both in vitro and ex
vivo, OA bone samples being more sensitive.
EFFECTS OF IL-17A AND TNF-α ON BV/TV RATIO
The key parameter for bone destruction is the quantification
of bone by histomorphometry. Bone volume over total volume
(BV/TV) ratio was calculated after 7 days of culture in the pres-
ence of IL-17A and/or TNF-α. In RA bone explants, IL-17A
alone or combined with TNF-α induced a significant decrease
in BV/TV ratio (0.65-fold with IL-17A and 0.53-fold with IL-
17A+TNF-α vs. 1-fold without cytokines, *p< 0.05) whereas in
OA bone explants, only the combination of cytokines induced
a significant decrease (0.79-fold with IL-17A+TNF-α vs. 1-
fold without cytokines, *p< 0.05) (Figure 5A). Representative
histomorphometric sections are shown in Figure 5B.
Thus, these results showed that TNF-α and IL-17A decreased
BV/TV ratio, with RA samples being more sensitive to their
destructive properties.
DISCUSSION
TNF-α is well known to induce bone degradation in arthritic dis-
eases, and IL-17A is now considered a new interesting target since
it shows synergy with TNF-α. The aim of this study was thus to
evaluate the effects of these cytokines in vitro using isolated FLS
and ex vivo using bone explants. Our results demonstrated that
isolated OA and RA synoviocytes were induced toward osteogenic
differentiation in the presence of the two cytokines via increas-
ing matrix mineralization and effects on osteogenic genes such as
BMP2, Wnt5a, and Runx2. On the other hand, the ex vivo model
showed rather a shift toward bone degradation.
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FIGURE 3 | Effects ofTNF-α and IL-17A on osteogenic marker genes.
FLS were cultured in osteogenic medium after 1 day of plating, in the
presence or absence of TNF-α 1 ng/ml and/or IL-17A 50 ng/ml for the
indicated times. Osteogenic gene expression of (A) BMP2, (B)Wnt5a, and
(C) Runx2 was measured by q-RT-PCR at 6, 12, and 24 h. Results were
analyzed using the Wilcoxon test. *p<0.05; **p<0.005 vs. without
cytokines. The bars of each graph represent mean+SEM.
Differences between OA- and RA-FLS and explants were
observed. RA-FLS were more sensitive to the effects of TNF-α and
IL-17A on cytokine production, ALP production but not matrix
formation. In RA bone samples, TNF-α and IL-17A induced
less ALP and cytokine production and more bone matrix loss
compared to OA samples.
The effect of TNF-α on whole bone destruction is in full agree-
ment with large use of TNF-α inhibitors in RA, but not in OA. In
addition, RA explants showed an increased sensitivity to cytokines.
Opposite results were obtained when isolated FLS were studied
for osteogenic differentiation. Since the two systems differ from
their cell complexity, we concluded that the key difference was
related to the presence or not of OCs, as the only cells able to
resorb bone.
Regarding the key genes associated with osteogenesis, BMP2
expression was previously found to be increased in different cell
types such as endothelial cells, synoviocytes, and chondrocytes
in response to TNF-α (37, 38). This report extends these find-
ings with the effects of TNF-α and IL-17A alone and combined
on BMP2 expression in FLS during osteogenesis. Here, TNF-α
and/or IL-17A induced early BMP2 expression with higher lev-
els in RA, compared to OA FLS. Wnt5a also showed an increase
in the presence of TNF-α alone or when combined to IL-17A
in both OA and RA FLS. Runx2 is a key transcription factor
for osteogenic differentiation (34). Indeed, in the presence of
osteogenic medium alone, Runx2 mRNA expression increased
over time in OA and RA FLS, which is consistent with the ongo-
ing osteogenic differentiation. Conversely, this enhancing effect
was inhibited in the presence of both cytokines again in OA and
RA FLS.
Addition of exogenous cytokines had a predicted effect on
endogenous production of other cytokines as part of an ampli-
fication mechanism. Numerous studies have described TNF-α as
a dominate inducer of IL-6 and IL-8 in synovium and IL-17A
shows enhancing and synergistic effects with TNF-α (39, 40).
Mouse and human joint explant studies suggested that IL-17A
alone can induce inflammatory response (17, 36). In this study,
TNF-α and/or IL-17A induced IL-6 and IL-8 production in both
isolated OA and RA FLS, with higher levels with RA FLS. These
results indicate that the addition of TNF-α and IL-17A to iso-
lated OA and RA FLS can induce local inflammation. IL-6 is a
well-known OC activating factor acting as a soluble link between
OBs and OCs. Combination of TNF-α and IL-17A specifically in
RA FLS and explants would then activate matrix destructing OCs
(41). IL-8 is a key chemotactic factor for neutrophils. Here, again
the combination of TNF-α and IL-17A specifically in RA FLS and
explants would then activate bone marrow progenitors leading
to the maturation of activation of neutrophils (42). In turn, this
would lead to bone edema, which is an early event at sites of bone
destruction in RA (43).
These effects on isolated cells might not reflect the cell interac-
tions that occur in vivo in bone. Indeed, in the ex vivo model, where
OBs and OCs interact together and with bone marrow cells, impor-
tant differences were noted. ALP increased in this ex vivo model
with the combination of both cytokines in OA but not RA sam-
ples while in vitro ALP increased in both FLS, especially from RA.
This already indicated a defect in bone formation in RA explants.
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FIGURE 4 | Effects ofTNF-α and IL-17A on IL-6 and IL-8 production.
(A) OA and (B) RA FLS were cultured in osteogenic medium for
14 days and bone samples (C,D) for 7 days, in the presence or
absence of TNF-α 1 ng/ml and/or IL-17A 50 ng/ml. IL-6 (C) and IL-8
(D) concentrations in supernatants were quantified by ELISA. Results
were analyzed using the Wilcoxon test. *p<0.05, **p<0.005 vs.
osteogenic medium alone. The bars of each graph represent
mean+SEM.
FIGURE 5 | Effects of IL-17A and/orTNF-α on BV/TV ratio. Bone samples
were cultured for 7 days in six well-plates, in the presence or absence of
IL-17A (50 ng/ml) and TNF-α (1 ng/ml) or both, then bone samples were used
for histomorphometric analysis. Bone volume over tissue volume (BV/TV) was
measured with an automatic image analyzer at low power field. (A) Results
were analyzed using the Wilcoxon test. *p<0.05 vs. without cytokines. The
bars of each graph represent mean+SEM. (B) Representative
histomorphometric sections from OA and RA bone samples with and without
the combination of IL-17A and TNF-α. Goldner’s staining shows trabecular
bone in green (10× magnification).
Results of IL-6 and IL-8 production in bone explants coincide with
those obtained in vitro, indicating local inflammation, leading to
OC activation and bone edema. This was indeed confirmed by
histomorphometric measurements of BV/TV ratio, which showed
that the combination of TNF-α and IL-17A significantly decreased
bone structure, specifically with RA samples.
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The interaction between different cell types combining bone
cells and bone marrow cells within the ex vivo model result in a
different pattern of response to the TNF-α and IL-17A effects. This
suggests that their net effects in arthritic diseases will depend on
a balance between osteogenesis and osteoclastogenesis processes
at different ratios. RA samples appear highly sensitive to the
effects of TNF-α and IL-17A. These results are in line with sev-
eral studies with RA-derived bone explants where inhibition of
TNF-α decreased inflammation as measured by levels of IL-6
and bone resorption markers. These inhibitory effects were fur-
ther enhanced with the combined blockade of IL-1 and IL-17A
(18). In the same RA ex vivo model of bone resorption, IL-4-
mediated inhibition of TNF-α level was associated with a 35%
inhibition in bone resorption with IL-4 (16). On the other side,
IL-17A enhanced bone resorption and decreased formation in
human RA bone explants. Blocking of bone-derived endogenous
IL-17A with specific inhibitors resulted in a protective inhibition of
bone destruction (17, 44). A recent study confirmed that the com-
bined blockade of TNFα and IL-17A is more effective in inhibiting
cytokine, chemokine, and matrix enzyme responses from human
mesenchymal cells and in blocking tissue destruction associated
with a mouse model of arthritis (45).
In conclusion, TNF-α and IL-17A induced osteogenic differen-
tiation of isolated FLS previously exposed to long-lasting disease
related stress of OA and RA diseases. In general, isolated RA-
FLS appeared more sensitive to the effects of TNF-α and IL-17A
compared to OA-FLS. In RA bone explants where OBs interact
with OCs and bone marrow cells, the addition of TNF-α and IL-
17A induced bone matrix destruction and lower ALP production,
indicating defective repair. In common OA, lower levels of these
cytokines would allow some repair activity as reflected by osteo-
phyte formation. From these findings, the combined blocking of
TNF-α and IL-17A may represent a new option for controlling
inflammatory bone disorders as in RA, psoriatic arthritis as well
as in ankylosing spondylitis and inflammatory subsets of OA and
even common osteoporosis.
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